Morepen Laboratories Announces Quarterly Results and Key Board Decisions

Morepen Laboratories Announces Quarterly Results and Key Board Decisions​

Morepen Laboratories Limited has released its unaudited financial results for the quarter ended June 30, 2026. The company's Board of Directors held a meeting on August 4, 2026, where key operational and corporate governance decisions were approved.

The Board meeting included the consideration and approval of the consolidated and standalone financial outcomes for the recent quarter, as well as setting the stage for upcoming shareholder meetings.

Financial Performance Snapshot (Quarter Ended June 30, 2026)​

The company reported strong performance across both its consolidated and standalone operations. A summary of the key financial metrics is provided below.

Consolidated Financial Results (Rs. in Lakhs)


Standalone Financial Results (Rs. in Lakhs)


The results show Net Profit After Tax and Total Comprehensive Income figures for the quarter, along with per share data. For instance, the consolidated EPS (Basic & Diluted) stood at 1.03, while the standalone Basic & Diluted EPS was 0.99.

Board Decisions and Corporate Governance Matters​

The Board meeting addressed several critical strategic and governance matters:

• Annual General Meeting (AGM): The notice of the company's 41st AGM is scheduled for September 26, 2026, which will be held through video conferencing or other audio-visual means.
• Dividend Record Date: A record date has been set for Saturday, September 19, 2026, to determine eligible members for receiving the final dividend for the financial year ended March 31, 2026, subject to member approval at the AGM.
• Management Re-appointment: The Board reviewed and approved the re-appointment of Mr. Sushil Suri as Chairman & Managing Director. This appointment is set for a further period of three years, effective from October 20, 2026, to October 19, 2029, subject to member approval at the 41st AGM.
• Business Divestiture: The meeting also reviewed the conditional extension of a timeline concerning the hiving off of the Medical Devices Business, a material related party transaction, into Morepen Medipath Limited (a subsidiary), which is planned as a going concern slump sale and is subject to shareholder approval.

The company maintains its engagement in the Pharmaceutical Business Segment.

MOREPENLAB Stock Price Movement​

Morepen Laboratories' shares are surging in live trading, currently at ₹66.18 as of 1:53 PM after rallying an impressive 14.80%. The stock is testing a major milestone, having reached the company's 52-week high and recording significant intraday momentum with nearly 34 million shares traded.